Page 358 - Read Online

Krastev et al. Hepatoma Res 2019;5:35 I http://dx.doi.org/10.20517/2394-5079.2019.02 Page 5 of 5

Conflicts of interest
All authors declared that there no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with
cirrhosis. N Engl J Med 2014;370:1973-82.
2. Deeks ED. Ombitasvir/Paritaprevir/Ritonavir PlusDasabuvir: A Review in Chronic HCV Genotype 1 Infection. Drugs 2015;75:1027-
38.
3. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat
patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-
blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-404.
4. Backus L, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness and predictors of sustained virological
response with all-oral therapy in 21,242 hepatitis C genotype-1 patients. Antivir Ther 2017;22:481-93.
5. Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo PA, Reddy KR, et al. Effectiveness of simeprevir plus sofosbuvir, with or without
ribavirin, in real-world patients with HCV Genotype 1 Infection. Gastroenterology 2015;150:419-29.
6. Foster GR, Irving WL, Cheung MCM, Walker AJ, Hudson BE, et al. Impact of direct acting antiviral therapy in patients with chronic
hepatitis C and decompensated cirrhosis. J Hepatol 2016;64:1224-31.
7. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
8. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-
related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
9. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-
antiviral agents. Gastroenterology 2017;153:996-1005.
10. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular
carcinoma. J Hepatol 2017;68:25-32.
11. Krastev Z, Jelev D, Antonov K, Petkova T, Atanasova E, et al. Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis
after complete destruction of hepatocellular carcinoma.World J Gastroenterol 2016;22:2630-5.
12. Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, et al. Recurrence of hepatocellular carcinoma after direct acting antiviral
treatment for hepatitis C virus infection: Literature review and risk analysis. Dig Liver Dis 2018;50:1105-14.
13. Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, et al. Direct-acting antivirals decreased tumor recurrence after initial
treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2017;62:2932-42.
14. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic
patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95.
15. Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus
eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther 2018;47:104-13.
16. Li T, Wang SK, Zhi XT, Zhou J, Dong ZR, et al. Positive HBcAb is associated with higher risk of early recurrence and poorer survival
aft er curative resection of HBV-related HCC. Liver Int 2016;36:284-92.
17. Wu T, Kwok RM, Tran TT. Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues. Am J
Gastroenterol 2017;112:1780-8.